Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking into genes in samples from younger patients with acute megakaryoblastic leukemia (AMKL).
Genetic: RNA analysis
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: gene rearrangement analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: laboratory biomarker analysis
|Official Title:||NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia|
- NUP98/JARID1A as a recurrent aberration in pediatric AMKL [ Designated as safety issue: No ]
|Study Start Date:||July 2012|
|Estimated Primary Completion Date:||September 2012 (Final data collection date for primary outcome measure)|
- To determine whether NUP98/JARID1A expression is a recurrent translocation in NUP98-rearranged cases in pediatric acute megakaryoblastic leukemia (AMKL).
- To screen the Children Oncology Group (COG) samples for genetic aberrations in pediatric AMKL.
OUTLINE: Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or mixed-lineage leukemia (MLL)-rearrangements, and other gene expression profiling by reverse-transcriptase polymerase chain reaction (RT-PCR) and karyotyping or fluorescence in situ hybridization ( FISH). Results are then compared with each patient's outcome data.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01642069
|Principal Investigator:||Soheil Meshinchi, MD||Fred Hutchinson Cancer Research Center|